Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies

Trial Profile

A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Jan 2019

At a glance

  • Drugs Cirmtuzumab (Primary) ; Ibrutinib
  • Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms CIRLL
  • Sponsors Oncternal Therapeutics, Inc.
  • Most Recent Events

    • 24 May 2018 According to an Oncternal Therapeutics media release, Pharmacyclics has committed to supplying ibrutinib to Oncternal during this trial.
    • 15 May 2018 According to an Oncternal Therapeutics mediia release, this study sites now include MD Anderson Cancer Center in Houston, where the first MCL patient was dosed, as well as Columbia University Medical Center and Northwell Health, both in New York. This study could serve as the basis of registration if robust.
    • 26 Mar 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top